NCT07138755View on ClinicalTrials.gov

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

August 31, 2030

Conditions
NSCLCSintilimabAdaptive Radiotherapy
Interventions
DRUG

Experimental

Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous） Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Pemetrexed, 500mg/m2 D1 IV Q3W(adenocarcinoma） Radiation:Adaptive radiotherapy with V20\<20%: 1.PGTV60-66Gy/2.0-2.2Gy/30F;PTV54Gy/1.8Gy/30F;2.PGTV54-66Gy/2.0-2.2Gy/30F；3.PGTV50Gy/2.0Gy/25F

All Listed Sponsors
lead

The Third Xiangya Hospital of Central South University

OTHER